Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P55 versus Cosentyx in moderate to severe plaque psoriasis
2024-513348-27-00Phase 3Completed
- Sponsor
- Celltrion
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CT-P55 in plaque psoriasis (2 arms), sponsored by Celltrion. Primary endpoint: Percent change from baseline in PASI score at Week 8. Started May 2025; status: completed.
02
Drugs
CT-P55
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-513348-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513348-27-00.